[1]
|
Lu, Y., Guan, L., Xu, M. and Wang, F. (2021) The Efficacy and Safety of Antibodies Targeting PD-1 for Treatment in Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis. Translational Oncology, 14, Article ID: 101083.
https://doi.org/10.1016/j.tranon.2021.101083
|
[2]
|
Luo, H., Lu, J., Bai, Y., Mao, T., Wang, J., Fan, Q., Zhang, Y., et al. (2021) Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA, 326, 916-925.
https://doi.org/10.1001/jama.2021.12836
|
[3]
|
Zhang, B., Qi, L., Wang, X., Xu, J., Liu, Y., Mu, L., et al. (2020) Phase II Clinical Trial Using Camrelizumab Combined with Apatinib and Chemotherapy as the First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma. Cancer Communications, 40, 711-720. https://doi.org/10.1002/cac2.12119
|
[4]
|
Yu, R., Wang, W., Li, T., Li, J., Zhao, K., Wang, W., et al. (2021) RATIONALE 311: Tislelizumab Plus Concurrent Chemoradiotherapy for Localized Esophageal Squamous Cell Carci-noma. Future Oncology, 17, 4081-4089.
https://doi.org/10.2217/fon-2021-0632
|
[5]
|
Shen, D., Chen, Q., Wu, J., Li, J., Tao, K. and Jiang, Y. (2021) The Safety and Efficacy of Neoadjuvant PD-1 Inhibitor with Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Journal of Gastrointestinal Oncology, 12, 1-10. https://doi.org/10.21037/jgo-20-599
|
[6]
|
Yang, H., Zhang, Q., Xu, M., Wang, L., Chen, X., Feng, Y., et al. (2020) CCL2-CCR2 Axis Recruits Tumor Associated Macro-phages to Induce Immune Evasion through PD-1 Signaling in Esophageal Carcinogenesis. Molecular Cancer, 19, Article No. 41. https://doi.org/10.1186/s12943-020-01165-x
|
[7]
|
Yuan, X., Zhang, A.Z., Ren, Y.L., Wang, X.L., Jiang, C.H., Yang, L., et al. (2021) Cytokine-Induced Killer Cells/ Dendritic Cells and Cytokine-Induced Killer Cells Immuno-therapy for the Treatment of Esophageal Cancer: A Meta- Analysis. Medicine, 100, Article ID: e24519. https://doi.org/10.1097/MD.0000000000024519
|
[8]
|
Wang, H., Xuan, T.-T., Chen, Y., Yu, H., Gu, T.-T., Zhou, G., et al. (2020) Investigative Therapy for Advanced Esophageal Cancer Using the Option for Combined Immunotherapy and Chemotherapy. Immunotherapy, 12, 697-703.
https://doi.org/10.2217/imt-2020-0063
|
[9]
|
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., et al. (2017) Prospects for Combining Targeted and Conventional Cancer Therapy with Immunotherapy. Na-ture Reviews Cancer, 17, 286-301.
https://doi.org/10.1038/nrc.2017.17
|
[10]
|
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., et al. (2019) Role of the Tumor Microenvironment in PD- L1/PD-1-Mediated Tumor Immune Escape. Molecular Cancer, 18, Article No. 10.
https://doi.org/10.1186/s12943-018-0928-4
|
[11]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.
https://doi.org/10.1016/j.cell.2011.02.013
|
[12]
|
Liu, Y. and Cao, X. (2016) Immunosuppressive Cells in Tumor Immune Escape and Metastasis. Journal of Molecular Medicine, 94, 509-522. https://doi.org/10.1007/s00109-015-1376-x
|
[13]
|
Harris, S.J., Brown, J., Lopez, J. and Yap, T.A. (2016) Immu-no-Oncology Combinations: Raising the Tail of the Survival Curve. Cancer Biology & Medicine, 13, 171-193. https://doi.org/10.20892/j.issn.2095-3941.2016.0015
|
[14]
|
马颖杰, 胡杰轩, 赵磊, 林海珊, 王婧, 等. 免疫治疗在晚期食管癌应用中的临床疗效及安全性分析[J]. 临床和实验医学杂志, 2022, 21(9): 955-959.
|
[15]
|
Lin, Y.-T., Chen, Y., Liu, T.-X., Kuang, F. and Huan, P. (2021) Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squa-mous Cell Carcinoma. Cancer Management and Research, 13, 8219-8230.
https://doi.org/10.2147/CMAR.S335515
|
[16]
|
Li, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lu, A. and Zhang, G. (2016) A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. International Journal of Molecular Sciences, 17, Article No. 1151. https://doi.org/10.3390/ijms17071151
|
[17]
|
Simsek, M., Tekin, S.B. and Bilici, M. (2019) Immunological Agents Used in Cancer Treatment. The Eurasian Journal of Medicine, 51, 90-94. https://doi.org/10.5152/eurasianjmed.2018.18194
|
[18]
|
Hsieh, C.-C., Hsu, H.-S., Li, A.F.-Y. and Chen, Y.-J. (2018) Clinical Relevance of PD-L1 and PD-L2 Overexpression in Patients with Esophageal Squamous Cell Carcinoma. Journal of Thoracic Disease 10, 4433-4444.
https://doi.org/10.21037/jtd.2018.06.167
|
[19]
|
Kollmann, D., Ignatova, D., Jedamzik, J., Chang, Y.-T., Jomrich, G., Baierl, A., et al. (2018) PD-L1 Expression Is an Independent Predictor of Favorable Outcome in Patients with Localized Esophageal Adenocarcinoma. Oncoimmunology, 7, Article ID: e1435226. https://doi.org/10.1080/2162402X.2018.1435226
|
[20]
|
Azuma, T., Yao, S., Zhu, G., Flies, A.S., Flies, S.J. and Chen, L. (2008) B7-H1 Is a Ubiquitous Antiapoptotic Receptor on Cancer Cells. Blood, 111, 3635-3643. https://doi.org/10.1182/blood-2007-11-123141
|
[21]
|
Hayashi, H. and Nakagawa, K. (2020) Combination Therapy with PD-1 or PD-L1 Inhibitors for Cancer. International Journal of Clinical Oncology, 25, 818-830. https://doi.org/10.1007/s10147-019-01548-1
|
[22]
|
Haanen, J.B. and Robert, C. (2015) Immune Checkpoint Inhibi-tors. In: Michielin, O. and Coukos, G., Eds., Progress in Tumor Research, Vol. 42, Karger, Basel, 55-66. https://doi.org/10.1159/000437178
|
[23]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[24]
|
Zhou, Y.-H., Li, J.-Y., Yan, J.-X., Guo, P., He, W.-W. and Liu, Y. (2022) Alleviation of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma and Its Relationship with Expression and Changes of PD-L1. Neoplasma. https://doi.org/10.4149/neo_2022_211223N1826
|
[25]
|
Muro, K., Kojima, T., Moriwaki, T., Kato, K., Nagashima, F., Kawakami, H., Ishihara, R., et al. (2022) Second-Line Pembrolizumab versus Chemotherapy in Japanese Patients with Advanced Esophageal Cancer: Subgroup Analysis from KEYNOTE-181. Esophagus, 19, 137-145. https://doi.org/10.1007/s10388-021-00877-3
|
[26]
|
Yan, X., Duan, H., Ni, Y., Zhou, Y., Wang, X., Qi, H., et al. (2022) Tislelizumab Combined with Chemotherapy as Neoadjuvant Therapy for Surgically Resectable Esophageal Can-cer: A Prospective, Single-Arm, Phase II Study (TD- NICE). International Journal of Surgery, 103, Article ID: 106680. https://doi.org/10.1016/j.ijsu.2022.106680
|
[27]
|
Huang, T.-X. and Fu, L. (2019) The Immune Landscape of Esophageal Cancer. Cancer Communications, 39, Article No. 79. https://doi.org/10.1186/s40880-019-0427-z
|
[28]
|
Huang, B., Shi, H., Gong, X., Yu, J., Xiao, C., Zhou, B., et al. (2021) Comparison of Efficacy and Safety between Pembrolizumab Combined with Chemotherapy and Simple Chemo-therapy in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma. Journal of Gastrointestinal Oncology, 12, 2013-2021. https://doi.org/10.21037/jgo-21-610
|
[29]
|
Wu, Z., Zheng, Q., Chen, H., Xiang, J., Hu, H., Li, H., et al. (2021) Efficacy and Safety of Neoadjuvant Chemotherapy and Immunotherapy in Locally Resectable Advanced Esopha-geal Squamous Cell Carcinoma. Journal of Gastrointestinal Oncology, 13, 3518-3528. https://doi.org/10.21037/jtd-21-340
|
[30]
|
Kato, K., Sun, J.-M., Shah, M.A., Enzinger, P.C., Adenis, A., Doi, T., et al. (2020) LBA8_PR Pembrolizumab Plus Chemotherapy versus Chemotherapy as First-Line Therapy in Patients with Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study. Annals of Oncology, 31, S1192-S1193. https://doi.org/10.1016/j.annonc.2020.08.2298
|
[31]
|
Kawazoe, A., Yamaguchi, K., Yasui, H., Negoro, Y., Azuma, M., Amagai, K., et al. (2020) Safety and Efficacy of Pembrolizumab in Combination with S-1 Plus Oxaliplatin as a First-Line Treatment in Patients with Advanced Gastric/ Gastroesophageal Junction Cancer: Cohort 1 Data from the KEYNOTE-659 Phase IIb Study. European Journal of Cancer, 129, 97-106. https://doi.org/10.1016/j.ejca.2020.02.002
|
[32]
|
Kojima, T., Hara, H., Tsuji, A., Yasui, H., Muro, K., Satoh, T., et al. (2022) First-Line Pembrolizumab + Chemotherapy in Japanese Patients with Advanced/Metastatic Esophageal Cancer from KEYNOTE-590. Esophagus.
https://doi.org/10.1007/s10388-022-00920-x
|